Medifast (NYSE:MED) Releases FY 2026 Earnings Guidance

04 May 2026, 17:18 by Amy Steele · The Cerbat Gem

Medifast (NYSE:MED – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of -2.750–1.550 for the period, compared to the consensus estimate of -1.980. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $275.3 million. Medifast also updated its Q2 2026 guidance to -1.000–0.500 EPS.

Medifast Trading Down 3.0%

Shares of MED traded down $0.33 during trading hours on Monday, hitting $10.58. The company had a trading volume of 150,459 shares, compared to its average volume of 241,666. The company has a market capitalization of $116.76 million, a PE ratio of -6.19 and a beta of 0.55. Medifast has a one year low of $9.22 and a one year high of $15.46. The company’s fifty day moving average price is $10.41 and its two-hundred day moving average price is $11.10.

Medifast (NYSE:MED – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The company had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Analysts forecast that Medifast will post -2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MED. Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Stephens reduced their price target on Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 19th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $12.00.

Read Our Latest Analysis on Medifast

Insider Transactions at Medifast

In related news, CEO Daniel R. Chard acquired 17,678 shares of the stock in a transaction dated Friday, March 20th. The stock was acquired at an average cost of $10.11 per share, for a total transaction of $178,724.58. Following the completion of the purchase, the chief executive officer owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Medifast

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after buying an additional 1,187 shares during the period. Man Group plc lifted its stake in Medifast by 0.6% during the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer’s stock valued at $2,784,000 after acquiring an additional 1,200 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Medifast by 2.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer’s stock valued at $749,000 after acquiring an additional 1,316 shares during the last quarter. Barclays PLC boosted its holdings in shares of Medifast by 10.6% in the 4th quarter. Barclays PLC now owns 16,769 shares of the specialty retailer’s stock valued at $179,000 after acquiring an additional 1,608 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Medifast in the third quarter worth $37,000. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

(Get Free Report)

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.